Medical tests

Ortho Clinical Diagnostics Named Transatlantic Legal Department of the Year by Panel of Leading Legal Journalists

Retrieved on: 
Friday, June 15, 2018
Medicine, Medical tests, Ortho Clinical Diagnostics, Health, Clinical medicine, Ortho, In vitro, Immunohaematology

RARITAN, N.J., June 15, 2018 /PRNewswire/ --Ortho Clinical Diagnostics (Ortho), a global leader of in vitro diagnostics, today announced that its in-house Legal and Compliance Department has been named the Transatlantic Legal Department of the Year.

Key Points: 
  • RARITAN, N.J., June 15, 2018 /PRNewswire/ --Ortho Clinical Diagnostics (Ortho), a global leader of in vitro diagnostics, today announced that its in-house Legal and Compliance Department has been named the Transatlantic Legal Department of the Year.
  • Ortho's team was selected by a panel of influential journalists from Legal Week and The American Lawyer, part of the ALM Media group.
  • The 2018 Transatlantic Awards honored Ortho's Legal and Compliance Department at their annual Gala on Thursday, June 14, 2018 in London.
  • Ortho Clinical Diagnostics is a global leader of in vitro diagnostics serving the clinical laboratory and immunohematology communities.

EMOSIS Announces an Exclusive Distribution Agreement with 5-Diagnostics and the Start of Commercialization

Retrieved on: 
Thursday, June 14, 2018
Medicine, Medical tests, Health, Biology, IVD, Molecular diagnostics, Hemostasis

Emosis starts selling HIT Confirm, Emosis' first test, through 5-Diagnostics' international network

Key Points: 
  • Emosis starts selling HIT Confirm, Emosis' first test, through 5-Diagnostics' international network
    Emosis, a medical device company specializing in cytomolecular diagnostics of hemostasis disorders, and 5-Diagnostics (5-D), a worldwide distributor for hemostasis products and In-Vitro Diagnostics (IVD), have signed an exclusive distribution agreement.
  • Thanks to this agreement that covers at least 36 countries, Emosis has commenced commercialization of the first Emo-test, HIT Confirm, in CE Mark-regulated countries.
  • "This agreement and the start of sales is a major leap forward for Emosis, after less than 30 months of operations!
  • Emosis is an innovative medical device/ IVD company specializing in cytomolecular diagnostics of hemostasis and thrombosis disorders.

Global Molecular Diagnostics Industry

Retrieved on: 
Monday, June 11, 2018
Medical tests, Cultural globalization, Human overpopulation, World population, Molecular diagnostics, Graph of a function, Biology

Table 1: Global In-Vitro Diagnostics Market by Segment (2017): Percentage Breakdown of Value Sales for Immunochemistry, Self-Monitoring Blood Glucose, Point-of-Care Diagnostics, Molecular Diagnostics, Tissue Diagnostics, Hematology, Microbiology, and Hemostasis (includes corresponding Graph/Chart)

Key Points: 
  • Table 1: Global In-Vitro Diagnostics Market by Segment (2017): Percentage Breakdown of Value Sales for Immunochemistry, Self-Monitoring Blood Glucose, Point-of-Care Diagnostics, Molecular Diagnostics, Tissue Diagnostics, Hematology, Microbiology, and Hemostasis (includes corresponding Graph/Chart)
    Table 2: Global In-Vitro Diagnostics Market by Geographic Region (2017): Percentage Breakdown of Value Sales for the United States, Europe, Asia-Pacific, Latin America, and Rest of World (includes corresponding Graph/Chart)
    Table 3: Global Aging Population (in Thousands) by Age Group: 1975-2050 (includes corresponding Graph/Chart)
    Table 4: Global Population Statistics for the 60+ Age Group by Region: 2017 (includes corresponding Graph/Chart)
    Table 5: Global Population Statistics for the 65+ Age Group by Select Countries: 2016 (includes corresponding Graph/Chart)
    Table 6: Global Life Expectancy at Birth (Years) by Geographic Region: 1950-2050 (includes corresponding Graph/Chart)
    Table 10: Comparison of Different Parameters for Select C. diff MDx Tests
    Table 11: HIV Prevalence and Incidence Statistics by Region: 2016 (includes corresponding Graph/Chart)
    Table 12: HIV Prevalence among the Global Adult Population: 2011-2016
    Molecular POC Testing for Infectious Diseases: Yet to Realize Its Full Potential

THE COMPANION DIAGNOSTICS (CDX) MARKET FORECAST 2018-2028

Retrieved on: 
Monday, June 11, 2018
Medicine, Clinical medicine, Health, Medical tests, Biomarkers, Chemical pathology, Personalized medicine, Theranostics, Companion diagnostic

A company profile gives you the following information where available:

Key Points: 
  • A company profile gives you the following information where available:
    What issues will affect the companion diagnostics industry?
  • Our new report discusses issues and events affecting the companion diagnostics market.
  • In summary, our 183-page report gives you the following knowledge:
    - Revenue forecasts to 2028 for the Companion Diagnostics market ' discover the industry's prospects, finding promising places for investments and revenues
    - Revenue forecasts to 2028 for each major submarket ' discover prospects for leading companion diagnostics products in the following areas: theranostics and other companion diagnostics.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

The EMEA 3D cone beam computed tomography systems market is projected to reach USD 300.4 million by 2023 from estimated USD 194.3 million in 2018, at a CAGR of 9.0%

Retrieved on: 
Thursday, June 7, 2018
Medicine, Medical tests, X-ray computed tomography, Medical imaging, Health, Cone beam computed tomography, Dentistry, CBCT, Clinical medicine, CT scan, Tomography, Jeffrey Siewerdsen

The EMEA 3D cone beam computed tomography systems market is projected to reach USD 300.4 million by 2023 from estimated USD 194.3 million in 2018, at a CAGR of 9.0%.

Key Points: 
  • The EMEA 3D cone beam computed tomography systems market is projected to reach USD 300.4 million by 2023 from estimated USD 194.3 million in 2018, at a CAGR of 9.0%.
  • The growing prevalence of dental disorders is also expected to boost the demand for advanced dental imaging systems such as 3D CBCT.
  • This report provides insights into the following pointers:
    Market Penetration: Comprehensive information on product portfolios offered by the top players in the EMEA 3D cone beam computed tomography systems market.
  • The report analyzes the EMEA 3D cone beam computed tomography systems market by application, end user, and region.

Avant Diagnostics to Present at LD Micro

Retrieved on: 
Friday, June 1, 2018
Medicine, Clinical medicine, Biology, Biotechnology, Biomarkers, Chemical pathology, Medical signs, Medical tests, Personalized medicine, Companion diagnostic

Time: 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time

Key Points: 
  • Time: 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time
    Avant Diagnostics, Inc. (Avant) is a healthcare data generating technology company that specializes in biomarker tests that are being planned or developed in multiple areas of oncology.
  • Avant provides personalized medicine data through its TheraLink assays, initially for breast cancer, to assist clinical oncologists in identifying likely responders, for over 70 FDA-approved drug treatment regimens.
  • Avant Diagnostics' Pharma Services Business will help drug companies accelerate their drug discovery programs and facilitate development of companion diagnostics.
  • Avant does not undertake an obligation to update or revise any forward-looking statement except as required by law.

ISBT Satellite Symposium Co-hosted by Ortho Clinical Diagnostics and Quotient Discusses Responding to the Challenges of Resource Constraints in Transfusion Diagnostics

Retrieved on: 
Friday, June 1, 2018
Medicine, Transfusion medicine, Anatomy, Hematology, Health, Medical tests, Ortho Clinical Diagnostics, Ortho, Blood, Blood transfusion, Immunohaematology, International Society of Blood Transfusion

RARITAN, N.J., June 1, 2018 /PRNewswire/ --Ortho Clinical Diagnostics (Ortho), a global leader of in vitro diagnostics, today announced that it will host a satellite symposium, co-sponsored with Quotient Limited (QTNT), titled "Responding to the Challenges of Resource Constraints in Transfusion Diagnostics", during the 35th International Congress of the International Society of Blood Transfusion (ISBT).

Key Points: 
  • RARITAN, N.J., June 1, 2018 /PRNewswire/ --Ortho Clinical Diagnostics (Ortho), a global leader of in vitro diagnostics, today announced that it will host a satellite symposium, co-sponsored with Quotient Limited (QTNT), titled "Responding to the Challenges of Resource Constraints in Transfusion Diagnostics", during the 35th International Congress of the International Society of Blood Transfusion (ISBT).
  • "The speakers at our symposium will identify the critical challenges facing transfusion medicine now and in the future," said Heidi Casaletto, vice president of Transfusion Medicine at Ortho.
  • Ortho will also share the following poster presentations at ISBT:
    Presenters: Tony S. Casina of Ortho Clinical Diagnostics, Raritan and Wim Malomgre of Ortho Clinical Diagnostics, Turnhout, Belgium
    Presenters: Tony S. Casina of Ortho Clinical Diagnostics, Raritan and Wim Malomgre of Ortho Clinical Diagnostics, Turnhout, Belgium
    Additionally, at ISBT, Ortho will feature the award-winning ORTHO VISION platform, which has received a string of accolades for its ability to innovate in transfusion medicine.
  • Ortho Clinical Diagnostics is a global leader of in vitro diagnostics serving the clinical laboratory and immunohematology communities.

Georgia Urology Physicians Encouraged By Prostate Cancer Screening Recommendations, Yet Urge Broader Vision Of Care

Retrieved on: 
Thursday, May 31, 2018
Medicine, Cancer, Clinical medicine, Prostate cancer, Men's Health, Medical tests, Prevention, Cancer screening, Prostate cancer screening, Urology, Screening

The latter, an independent group of experts, released a statement recommending men between the ages of 55 and 69 consult with their physicians about prostate cancer screening.

Key Points: 
  • The latter, an independent group of experts, released a statement recommending men between the ages of 55 and 69 consult with their physicians about prostate cancer screening.
  • Georgia Urology physicians agree this is a step in the right direction, but urge a broader vision of care.
  • "Georgia Urology agrees that there should be new guidelines for prostate cancer screening," said Dr. Barry Zisholtz, a partner and urology surgeon at Georgia Urology.
  • The refined guidelines come on the heels of the 2012 recommendation advising against routine prostate cancer screening due to risks related to treatment and testing.

Abbott Introduces the Afinion™ 2 Analyzer Rapid Test System for Diabetes Management

Retrieved on: 
Thursday, May 31, 2018
Health, Medicine, Diabetes, Medical tests, Blood tests, Medical technology, Nursing informatics, Glycated hemoglobin, Hospital information system, Health care

ABBOTT PARK, Ill., May 31, 2018 /PRNewswire/ --Abbott (NYSE: ABT)announced today the launch of its Afinion 2 analyzer in the U.S., the newest generation of the Afinion test system.

Key Points: 
  • ABBOTT PARK, Ill., May 31, 2018 /PRNewswire/ --Abbott (NYSE: ABT)announced today the launch of its Afinion 2 analyzer in the U.S., the newest generation of the Afinion test system.
  • Along with providing rapid results, the Afinion 2 platform now also offers all-in-one connectivity to LIS/HIS (laboratory and hospital information systems) and a sleeker, quieter experience for clinicians and patients.
  • Healthcare professionals can use the Afinion 2 analyzer in a wide range of out-patient settingsincluding physician offices, clinics, community health centers, hospitals and long-term care facilities.
  • "By delivering rapid HbA1c and ACR test results, the Afinion 2 analyzer does more than streamline care; its life-changing technology helps people living with diabetes get the most out of their healthcare visits," said Elizabeth Balthrop, divisional vice president, Cardiometabolic and Informatics, Abbott.

The global molecular diagnostics market is projected to grow at a CAGR of 8.4%

Retrieved on: 
Wednesday, May 30, 2018
Medicine, Medical tests, Biotechnology, Biology, Molecular diagnostics, Diagnosis, Health

The global molecular diagnostics market is expected to reach USD 11.54 billion by 2023 from USD 7.71 billion in 2018, at a CAGR of 8.4%.

Key Points: 
  • The global molecular diagnostics market is expected to reach USD 11.54 billion by 2023 from USD 7.71 billion in 2018, at a CAGR of 8.4%.
  • Based on product and service, the molecular diagnostics market is segmented into reagents and kits, instruments, and services and software.The reagents and kits segment is expected to account for the largest share of the global molecular diagnostics market in 2018.
  • Asia Pacific is expected to register the highest CAGR in the global molecular diagnostics market during the forecast period.
  • The report analyzes the market, by product & service, application, technology, end user, and region
    Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and product launches in the global molecular diagnostics market
    Market Diversification: Exhaustive information about new products, untapped regions, and recent developments in the global molecular diagnostics market